Evidence map›Paper›PMID 33841891›Full record

ArticleObesity science & practice2021

Dynamics of hepatic steatosis resolution and changes in gut microbiome with weight loss in nonalcoholic fatty liver disease.

Jaideep Behari, Lisa Graham, Renwei Wang, Claudiu Schirda, Amir A Borhani, Barbara A Methé, Kelvin Li, Alison Morris, Hung N Luu, Sabrina Palmieri and 1 more

Open access · goldAbstract read
In one paragraph

Article in Obesity science & practice, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.7field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Frontiers in microbiology · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Jaideep BehariDepartment of Medicine, Division of Gastroenterology, Hepatology, and Nutrition University of Pittsburgh School of Medicine Pittsburgh Pennsylvania USA.ORCID https://orcid.org/0000-0001-8077-5137
Lisa GrahamDepartment of Medicine, Division of Gastroenterology, Hepatology, and Nutrition University of Pittsburgh School of Medicine Pittsburgh Pennsylvania USA.
Renwei WangCancer Epidemiology and Prevention Program University of Pittsburgh Medical Center Hillman Cancer Center Pittsburgh Pennsylvania USA.
Claudiu SchirdaDepartment of Radiology University of Pittsburgh School of Medicine Pittsburgh Pennsylvania USA.ORCID https://orcid.org/0000-0002-5036-0640
Amir A BorhaniDepartment of Radiology University of Pittsburgh School of Medicine Pittsburgh Pennsylvania USA.
Barbara A MethéCenter for Medicine and the Microbiome University of Pittsburgh Pittsburgh Pennsylvania USA.
Kelvin LiCenter for Medicine and the Microbiome University of Pittsburgh Pittsburgh Pennsylvania USA.
Alison MorrisCenter for Medicine and the Microbiome University of Pittsburgh Pittsburgh Pennsylvania USA.
Hung N LuuCancer Epidemiology and Prevention Program University of Pittsburgh Medical Center Hillman Cancer Center Pittsburgh Pennsylvania USA.
Sabrina PalmieriDepartment of Medicine, Division of Gastroenterology, Hepatology, and Nutrition University of Pittsburgh School of Medicine Pittsburgh Pennsylvania USA.
Jian-Min YuanCancer Epidemiology and Prevention Program University of Pittsburgh Medical Center Hillman Cancer Center Pittsburgh Pennsylvania USA.
University of Pittsburgh · USUPMC Hillman Cancer Center · US

Funding

Pittsburgh Liver Research CenterP30DK120531 · NIDDK · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI DAVID A GELLER · 2019 to 2026
$10.9M
NIDDK NIH HHS P30 DK120531
6 · The paper itself

Abstract

backgroundWeight loss is recommended as the primary treatment for nonalcoholic fatty liver disease (NAFLD). However, the magnitude and velocity of hepatic steatosis resolution with weight loss is unclear, making it difficult to counsel patients seeking weight loss for treatment of NAFLD. The aim of this study was to determine the rate of hepatic steatosis improvement and stool microbiome changes associated with rapid diet-induced weight loss in NAFLD.

methodsFourteen NAFLD patients (mean ± standard deviation, body mass index [BMI] 36.4 ± 4 kg/m

resultsAt Week 12, mean (95% confidence interval) weight loss was -13.4 (-15.2, -11.5)% and CAP score -26.6 (-35.6, -17.6)% (both

conclusionsDiet-induced intensive weight loss is associated with rapid improvement and complete resolution of hepatic steatosis and decreased stool microbial diversity. These findings highlight the dynamic nature of hepatic fat and may help clinicians to develop evidence-based treatment goals for patients with NAFLD and obesity who undertake weight loss interventions. Further research is warranted to understand the effects of intensive weight loss and gut microbiome changes on long-term NAFLD resolution.

Indexed as

liver diseasemicrobiomeobesityweight loss

Identifiers

PMID33841891
PMCPMC8019274
OpenAlexW3115255698

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.